enGene Therapeutics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ENGNW | CADL | URGN | ELVN | XBIO | BIIB | |
|---|---|---|---|---|---|---|
| Market cap | — | 625.92M | 1.29B | 3.33B | 4.17M | 36.63B |
| P/E (TTM) | — | — | — | — | — | 107.3 |
| Forward P/E | — | -13.1 | 9.6 | -19.6 | -2.7 | 15.2 |
| Price/book | 0.1 | 4.9 | -12.1 | 3.7 | 0.7 | 1.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | — | +83.20% | +22.09% | +158.20% | −26.10% | +62.35% |
| Today | 0.00% | −9.61% | −8.28% | −3.83% | −11.44% | −2.61% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All ENGNW news ›enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment - Slideshow
2026-10-19. The following slide deck was published by enGene Therapeutics Inc. The following slide deck was published by enGene Therapeutics Inc. in conjunction with this event.
From the 4Search news index, newest first.